# A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

> **NCT05312632** · PHASE4 · COMPLETED · sponsor: **Eisai Korea Inc.** · enrollment: 201 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Safinamide Mesilate

## Key facts

- **NCT ID:** NCT05312632
- **Lead sponsor:** Eisai Korea Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-05
- **Primary completion:** 2023-05-25
- **Final completion:** 2023-05-25
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2024-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05312632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05312632, "A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05312632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*